The hiring of a key Merck scientist and potential for combination cancer immunotherapy explain the recent rebound in Advaxis' stock price.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
The J.P. Morgan Healthcare Conference is in the rear-view mirror, but issues, controversies and questions raised during the annual gathering of the biotech sector tribe will linger through the year.
Express Scripts CEO George Paz doesn't mince words about the need to cap specialty drug pricing during his talk Tuesday at the J.P. Morgan Healthcare Conference.
Aegerion slipped disclosure of the SEC probe into an regulatory filing last night.
Included in Bienaime's investor presentation is two slides making a direct data comparison between BioMarin's (soon to be) Duchenne muscular dystrophy drug drisapersen and Sarepta's competing DMD drug eteplirsen.
The timing of the Afrezza commercial launch is still a mystery following Sanofi's presentation.
Celgene CEO Bob Hugin just wrapped his presentation at the J.P. Morgan Healthcare Conference by reiterating 2017 financial guidance and offering new, longer-term guidance for 2020.
The company presents at the J.P. Morgan Healthcare Conference on Thursday.
Lung cancer is a larger commercial market opportunity for Bristol's Opdivo and Merck's Keytruda.